Caradigm, BIO-key International ink OEM agreement
BIO-key International has executed an OEM agreement with Caradigm in regards to BIO-key’s Identity and Access Management (IAM) suite for healthcare organizations.
A Microsoft and GE Healthcare company, Caradigm will offer BIO-key’s fingerprint biometric technology with its single sign-On solution, enabling hospitals and health systems to comply with fereal and state government regulations. Specifically, says the company, Caradigm IAM customers will be able to meet requirements associated with authenticating the identity of caregivers writing electronic prescriptions of controlled substances (EPCS), as the Drug Enforcement Administration requires caregivers to perform two-factor authentication for EPCS, and some states also requires two-factor for all electronic prescriptions.
“We are very enthused about the OEM relationship with Caradigm as we help to change the way healthcare professionals manage information and access patient records,” Mike DePasquale, CEO, BIO-key said. The company is building from a significant presence and installed base of millions of users. Our goal is to provide Caradigm customers with the fastest, most convenient method available to support streamlined workflow and role based access. Our relationship with Caradigm demonstrates the viability of our revenue and operating model, as well as a validation of our premier fingerprint and authentication technologies.”
Caradign allows caregivers to rapidly access applications and patient data without signing on to each application, which can help caregivers improve patient safety, reduce medical errors. Based on the flexibility of BIO-key’s technology, caregivers can perform authentication with 30 different supported fingerprint readers.
BIO-key has had a busy month. Reported previously, the company announced that Miller-Keystone Blood Center selected BIO-key’s TruDonor system at its centers across Pennsylvania and New Jersey.
Also reported previously, the company has boasted over $1 million in order from healthcare technology providers and blood centers in the fourth quarter of 2012.
Comments